Prognostic value of histology in patients with non-small cell lung cancer

被引:45
作者
Charloux, A
Hedelin, G
Dietemann, A
Ifoundza, T
Roeslin, N
Pauli, G
Quoix, E
机构
[1] HOP UNIV STRASBOURG, F-67091 STRASBOURG, FRANCE
[2] FAC MED STRASBOURG, LAB EPIDEMIOL & SANTE PUBL, F-67085 STRASBOURG, FRANCE
[3] UNIV STRASBOURG 1, SERV CHIRURG THORAC, F-67091 STRASBOURG, FRANCE
关键词
non small cell lung cancer; adenocarcinoma; bronchioloalveolar carcinoma; prognosis; neoplasm staging;
D O I
10.1016/S0169-5002(97)00655-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To evaluate the impact of non-small cell lung cancer (NSCLC) histological subtypes on survival, we performed a retrospective multivariate analysis of survival in 361 patients with a NSCLC diagnosed in 1987 and 1988 at the University Hospital in Strasbourg, France. There were 262 (73%) squamous cell carcinomas (SQ), 59 (16%) adenocarcinomas other than bronchioloalveolar carcinoma (ADOBAC), 24 (7%) bronchioloalveolar carcinoma (BAG) and 16 (4%) large cell carcinomas (LC). The proportion of metastatic disease was significantly higher in the ADOBAC group than in the SQ group (30% vs. 15%, P < 0.001). In operated patients, only extent of disease and age were independent prognostic factors. In patients with unresectable NSCLC, extent of disease had also the heaviest impact on survival. However, in these unresected patients, ADOBAC had a pejorative impact on survival, in contrast to BAC which was of better prognosis, If these results are confirmed by prospective studies, this will support stratification according to histological subtypes in clinical trials involving inoperable NSCLC patients. (C) 1997 Elsevier Science Ireland Ltd.
引用
收藏
页码:123 / 134
页数:12
相关论文
共 38 条
[1]   SURVIVAL DETERMINANTS IN EXTENSIVE-STAGE NON-SMALL-CELL LUNG-CANCER - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1618-1626
[2]  
[Anonymous], 1982, AM J CLIN PATHOL, V77, P123
[3]   PRETREATMENT PROGNOSTIC FACTORS IN STAGE-III NON-SMALL-CELL LUNG-CANCER PATIENTS RECEIVING COMBINED MODALITY TREATMENT [J].
BONOMI, P ;
GALE, M ;
ROWLAND, K ;
TAYLOR, SG ;
PURL, S ;
REDDY, S ;
LEE, MS ;
PHILLIPS, A ;
KITTLE, CF ;
WARREN, W ;
FABER, LP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (02) :247-252
[4]  
CHARLOUX A, IN PRESS INT J EPIDE
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]   CLINICAL INDICATORS OF PROGNOSIS IN UNRESECTED LUNG-CANCER [J].
COY, P ;
ELWOOD, JM ;
COLDMAN, AJ .
CHEST, 1981, 80 (04) :453-458
[7]  
DEPIERRE A, 1992, C SOC PNEUM LANG FRA, P163
[8]  
DUMONT P, 1989, REV MAL RESPIR, V6, P329
[9]   ALVEOLAR CARCINOMA - A REVIEW [J].
EDWARDS, CW .
THORAX, 1984, 39 (03) :166-174
[10]   SITES OF RECURRENCE IN RESECTED STAGE-I NON-SMALL-CELL LUNG-CANCER - A GUIDE FOR FUTURE STUDIES [J].
FELD, R ;
RUBINSTEIN, LV ;
WEISENBERGER, TH .
JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (12) :1352-1358